150 related articles for article (PubMed ID: 27440071)
41. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide.
Pamonsinlapatham P; Decroix N; Mihaila-Amrouche L; Bouvet A; Bouvet JP
Scand J Immunol; 2004 May; 59(5):504-10. PubMed ID: 15140061
[TBL] [Abstract][Full Text] [Related]
42. Polyethylenimine: An Intranasal Adjuvant for Liposomal Peptide-Based Subunit Vaccine against Group A
Dai CC; Yang J; Hussein WM; Zhao L; Wang X; Khalil ZG; Capon RJ; Toth I; Stephenson RJ
ACS Infect Dis; 2020 Sep; 6(9):2502-2512. PubMed ID: 32786276
[TBL] [Abstract][Full Text] [Related]
43. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
Xu JH; Dai WJ; Chen B; Fan XY
Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
[TBL] [Abstract][Full Text] [Related]
44. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
Zhong W; Skwarczynski M; Toth I
Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
[TBL] [Abstract][Full Text] [Related]
45. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
[TBL] [Abstract][Full Text] [Related]
46. Strategies in the development of vaccines to prevent infections with group A streptococcus.
Good MF; Batzloff MR; Pandey M
Hum Vaccin Immunother; 2013 Nov; 9(11):2393-7. PubMed ID: 23863455
[TBL] [Abstract][Full Text] [Related]
47. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system.
Nally JE; Artiushin S; Sheoran AS; Burns PJ; Simon B; Gilley RM; Gibson J; Sullivan S; Timoney JF
Vaccine; 2000 Oct; 19(4-5):492-7. PubMed ID: 11027813
[TBL] [Abstract][Full Text] [Related]
48. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
49. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.
Olive C; Batzloff MR; Horváth A; Wong A; Clair T; Yarwood P; Toth I; Good MF
Infect Immun; 2002 May; 70(5):2734-8. PubMed ID: 11953422
[TBL] [Abstract][Full Text] [Related]
50. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
[TBL] [Abstract][Full Text] [Related]
52. Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems.
Figueiredo L; Cadete A; Gonçalves LM; Corvo ML; Almeida AJ
Vaccine; 2012 Oct; 30(46):6551-8. PubMed ID: 22947139
[TBL] [Abstract][Full Text] [Related]
53. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
[TBL] [Abstract][Full Text] [Related]
54. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
55. The quest for GAS vaccine.
Pandey M; Good MF
Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
[No Abstract] [Full Text] [Related]
56. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
57. Novel platform technology for modular mucosal vaccine that protects against streptococcus.
Zaman M; Ozberk V; Langshaw EL; McPhun V; Powell JL; Phillips ZN; Ho MF; Calcutt A; Batzloff MR; Toth I; Hill GR; Pandey M; Good MF
Sci Rep; 2016 Dec; 6():39274. PubMed ID: 27976706
[TBL] [Abstract][Full Text] [Related]
58. The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines.
Yang J; Boer JC; Khongkow M; Phunpee S; Khalil ZG; Bashiri S; Deceneux C; Goodchild G; Hussein WM; Capon RJ; Ruktanonchai U; Plebanski M; Toth I; Skwarczynski M
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851183
[TBL] [Abstract][Full Text] [Related]
59. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
60. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
